Last reviewed · How we verify

NCT05313269: ISAFE

Inter-fascial Plane Between the SArtorius Muscle and FEmoral Artery (ISAFE)

Completed NA Last updated 6 June 2023
What this trial tests

NA trial testing ISAFE technique for adductor canal catheter insertion in Anesthesia, Conduction in 100 participants. Completed in 28 March 2023.

Timeline
28 April 2022
Primary endpoint
28 February 2023
28 March 2023

Quick facts

Lead sponsorUniversity of Toronto
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment100
Start date28 April 2022
Primary completion28 February 2023
Estimated completion28 March 2023
Sites1 location across Canada

Drugs / interventions tested

Conditions studied

Sponsor

University of Toronto

Who can join

21 and older, any sex, with Anesthesia, Conduction or Arthroplasty, Replacement, Knee. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Total knee arthroplasty (TKA) is a frequent performed surgery. Adequate pain management is an important feature. Analgesic duration of single shot nerve blocks is limited to no more than 24h. Conversely, the use of continuous nerve block (CNB) through a perineural catheter and infusion of local anesthetic may increase duration of analgesia and provide better outcomes. Continuous adductor canal block (CACB) has been proven superior when compared to single-injection adductor canal block (SACB) for TKA analgesia. However, safety concerns such as intravenous insertion, nerve injury, or catheter displacement must always be considered. The purpose of this study is to evaluate the Inter-fascial Plane between SArtorius Muscle and FEmoral Artery (ISAFE) approach for adductor canal catheter placement, in terms of catheter dislodgment, clinical effectiveness and complications, in comparison with the classical approach, as TKA postoperative analgesia modality. We hypothesize that ISAFE approach can result in a smaller rate of dislodgments in the way that it increases the clinical benefit of CACB.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other University of Toronto trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05313269.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing